---
layout: default
title: Deferasirox
parent: Model Prediction Only (L5)
nav_order: 104
evidence_level: L5
indication_count: 5
---

# Deferasirox
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **5** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# DEFERASIROX: Drug Repurposing Assessment Report

> ⚠️ **Data Completeness Warning**: This Evidence Pack is missing critical fields (TxGNN predicted indications, original indication, MOA, safety warnings); the following report is presented based on available data, with all data gaps marked.

---

## Summary

Deferasirox is an oral iron chelator with global use in treating chronic iron overload from long-term blood transfusions (transfusional hemosiderosis). This Evidence Pack (v4, created on 2026-04-20) **does not contain any TxGNN drug repurposing prediction results** (`predicted_indications` is empty), and the drug's original indication, MOA, and safety data are not fully recorded. Therefore, this report can only present basic drug information, **and cannot yet conduct a complete assessment of new indications**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original indication | Data gap (Evidence Pack not provided) |
| Predicted new indications | **None** (TxGNN prediction results not recorded) |
| TxGNN prediction score | N/A |
| Evidence level | **L5** (model prediction not yet executed) |
| Taiwan market status | ✗ Not marketed (TFDA records show no approval) |
| Number of approvals | 0 |
| Recommended decision | **Hold** |

---

## Mechanism of Action

The Evidence Pack currently does not provide detailed mechanism of action data (DG002: High severity).

Based on public knowledge, Deferasirox is a tridentate iron chelator that selectively binds ferric iron ions (Fe³⁺), forming stable 2:1 complexes that are excreted via faeces, thereby reducing iron accumulation in the body. Its originally developed indications are:

- **Iron overload due to chronic transfusion** (transfusional hemosiderosis)
- **Iron overload in non-transfusion-dependent thalassemia**

Detailed MOA data requires querying the DrugBank API (DB01609) to complete.

---

## TxGNN Prediction Results

The `predicted_indications` field in this Evidence Pack is an empty array, **with no TxGNN predicted new indications recorded**.

Possible reasons:
1. TxGNN prediction workflow has not yet been executed for Deferasirox
2. Prediction results were not included in this data package
3. Pipeline data integration step was omitted

**Recommended action**: Re-execute the TxGNN prediction workflow to confirm DB01609 has been correctly input into the knowledge graph.

---

## Taiwan Market Information

TFDA query results (query date: 2026-03-29) show that Deferasirox **has no approved pharmaceutical licence in Taiwan**.

| Item | Result |
|------|--------|
| Number of permits | 0 |
| Market status | Not marketed |
| Dosage form records | None |

> Note: Deferasirox has been approved for marketing outside Taiwan (e.g., by FDA, EMA, PMDA in Japan), with brand names including **Exjade** (film-coated tablets/dispersible tablets) and **Jadenu** (film-coated tablets); however, Taiwan currently has no approval records.

---

## Safety Considerations

All safety data in this Evidence Pack represent data gaps and cannot be extracted from available data.

Based on globally known safety information for Deferasirox (for reference only, not from this Evidence Pack):

- **Nephrotoxicity**: May cause elevated serum creatinine; regular renal function monitoring is necessary
- **Hepatotoxicity**: Monitoring of liver function (ALT/AST) is required
- **Gastrointestinal adverse effects**: Nausea, vomiting, and diarrhea are common
- **Rash**: Allergic skin reactions

⚠️ Formal safety assessment can only be conducted after completing TFDA package insert warnings (DG001: Blocking severity).

---

## Data Gap Inventory

| Gap ID | Item | Severity | Impact | Recommended completion method |
|--------|------|----------|--------|------------------------------|
| DG001 | TFDA package insert warnings/contraindications | 🔴 Blocking | Cannot conduct safety preliminary assessment | Download and parse TFDA package insert PDF |
| DG002 | Mechanism of action (MOA) | 🟠 High | Limits mechanistic-link analysis | Query the DrugBank API (DB01609) |
| DG003 | TxGNN prediction results | 🔴 Blocking | No predicted new indications available for assessment | Re-execute TxGNN prediction workflow |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack lacks TxGNN prediction results (`predicted_indications` is empty), and the original indication, MOA, and safety warnings are not fully recorded. At this stage, no meaningful drug repurposing assessment can be conducted.

**The following data must be completed before proceeding:**

1. **Re-execute TxGNN prediction**: Confirm that Deferasirox (DB01609) has been correctly entered into the knowledge graph, and obtain the list of predicted new indications
2. **Complete MOA data**: Query the DrugBank API (DB01609) to obtain detailed mechanism of action description
3. **Collect safety data**: Download and parse the TFDA package insert PDF to complete warnings and contraindications fields
4. **Confirm Taiwan market viability**: Evaluate whether new drug application is required, or whether current regulatory pathways apply
5. **Complete Evidence Pack**: Once the above data are collected, regenerate Evidence Pack v5 and re-produce a complete assessment report

---

*This report was produced based on Evidence Pack v4 (2026-04-20) data. It is for research reference only and does not constitute medical advice. Formal clinical application requires complete clinical verification.*

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

